1. Home
  2. EVAX vs BCDA Comparison

EVAX vs BCDA Comparison

Compare EVAX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • BCDA
  • Stock Information
  • Founded
  • EVAX 2008
  • BCDA N/A
  • Country
  • EVAX Denmark
  • BCDA United States
  • Employees
  • EVAX N/A
  • BCDA N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • BCDA Health Care
  • Exchange
  • EVAX Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • EVAX 15.1M
  • BCDA 10.1M
  • IPO Year
  • EVAX 2021
  • BCDA N/A
  • Fundamental
  • Price
  • EVAX $2.65
  • BCDA $2.33
  • Analyst Decision
  • EVAX Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • EVAX 2
  • BCDA 1
  • Target Price
  • EVAX $10.00
  • BCDA $25.00
  • AVG Volume (30 Days)
  • EVAX 103.4K
  • BCDA 239.0K
  • Earning Date
  • EVAX 08-13-2025
  • BCDA 08-12-2025
  • Dividend Yield
  • EVAX N/A
  • BCDA N/A
  • EPS Growth
  • EVAX N/A
  • BCDA N/A
  • EPS
  • EVAX N/A
  • BCDA N/A
  • Revenue
  • EVAX $3,293,000.00
  • BCDA $3,000.00
  • Revenue This Year
  • EVAX N/A
  • BCDA N/A
  • Revenue Next Year
  • EVAX N/A
  • BCDA N/A
  • P/E Ratio
  • EVAX N/A
  • BCDA N/A
  • Revenue Growth
  • EVAX 2555.64
  • BCDA N/A
  • 52 Week Low
  • EVAX $1.20
  • BCDA $1.63
  • 52 Week High
  • EVAX $17.75
  • BCDA $4.66
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 55.56
  • BCDA 58.67
  • Support Level
  • EVAX $2.26
  • BCDA $1.98
  • Resistance Level
  • EVAX $2.60
  • BCDA $2.45
  • Average True Range (ATR)
  • EVAX 0.21
  • BCDA 0.17
  • MACD
  • EVAX -0.02
  • BCDA 0.04
  • Stochastic Oscillator
  • EVAX 51.32
  • BCDA 88.00

About EVAX Evaxion Biotech

Evaxion AS is in the field of oncology. It used the AI-Immunology platform.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: